Fibroblast Growth Factor 23 is a Potential Prognostic Biomarker in Uterine Sarcoma
Background Uterine sarcoma (US) is a highly malignant cancer with poor prognosis and high mortality in women. In this study, we evaluated the expression of human fibroblast growth factor 23 (FGF23) in different US subtypes and the relationship between survival and clinicopathological characteristics...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2024-04-01
|
| Series: | Technology in Cancer Research & Treatment |
| Online Access: | https://doi.org/10.1177/15330338241245924 |
| _version_ | 1797209881378291712 |
|---|---|
| author | Ling Yang MS Ying Cai MS Yunjia Wang MS Yue Huang MS Chi Zhang MS Hu Ma MD, PhD Jian-Guo Zhou MD, PhD |
| author_facet | Ling Yang MS Ying Cai MS Yunjia Wang MS Yue Huang MS Chi Zhang MS Hu Ma MD, PhD Jian-Guo Zhou MD, PhD |
| author_sort | Ling Yang MS |
| collection | DOAJ |
| description | Background Uterine sarcoma (US) is a highly malignant cancer with poor prognosis and high mortality in women. In this study, we evaluated the expression of human fibroblast growth factor 23 (FGF23) in different US subtypes and the relationship between survival and clinicopathological characteristics. Methods We conducted a comparative analysis of FGF23 gene expression in different pathological types of US. Utilizing a cohort from The Cancer Genome Atlas of 57 patients, a 50-patient microarray dataset (GSE119043) from the Gene Expression Omnibus and a Suining cohort of 44 patients, we analyzed gene expression profiles and corresponding clinicopathological information. Immunohistochemistry was used to examine the expression level of FGF23 in four US subtypes. Survival analysis was used to assess the relationship between FGF23 expression and prognosis in US patients. Results Compared with uterine normal smooth muscle and uterine leiomyoma, FGF23 expression was significantly upregulated in US and was differentially expressed in four US subtypes. Uterine carcinosarcoma exhibited the highest expression of FGF23 among the subtypes. Survival analysis revealed no correlation between FGF23 expression and either overall survival or progression-free survival in US ( P > 0.05). Similar results were obtained from the validation cohorts. Univariate and multivariate analyses showed no significant correlation between FGF23 expression and the US prognosis. Tumor stage, CA125, and tumor recurrence were independent prognostic factors for survival of US patients. Conclusion FGF23 was highly expressed in US and was promising as a novel potential biomarker for the diagnosis and prognosis of US. |
| first_indexed | 2024-04-24T10:01:45Z |
| format | Article |
| id | doaj.art-2aa13c2a1a7845d5af5bd87ff0b3dc3b |
| institution | Directory Open Access Journal |
| issn | 1533-0338 |
| language | English |
| last_indexed | 2024-04-24T10:01:45Z |
| publishDate | 2024-04-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Technology in Cancer Research & Treatment |
| spelling | doaj.art-2aa13c2a1a7845d5af5bd87ff0b3dc3b2024-04-13T10:05:05ZengSAGE PublishingTechnology in Cancer Research & Treatment1533-03382024-04-012310.1177/15330338241245924 Fibroblast Growth Factor 23 is a Potential Prognostic Biomarker in Uterine SarcomaLing Yang MS0Ying Cai MS1Yunjia Wang MS2Yue Huang MS3Chi Zhang MS4Hu Ma MD, PhD5Jian-Guo Zhou MD, PhD6 Department of Pathology, , Suining, China Department of Oncology, , Zunyi, China Department of Oncology, , Zunyi, China Department of Oncology, , Zunyi, China Department of Oncology, , Zunyi, China Department of Oncology, , Zunyi, China Department of Oncology, , Zunyi, ChinaBackground Uterine sarcoma (US) is a highly malignant cancer with poor prognosis and high mortality in women. In this study, we evaluated the expression of human fibroblast growth factor 23 (FGF23) in different US subtypes and the relationship between survival and clinicopathological characteristics. Methods We conducted a comparative analysis of FGF23 gene expression in different pathological types of US. Utilizing a cohort from The Cancer Genome Atlas of 57 patients, a 50-patient microarray dataset (GSE119043) from the Gene Expression Omnibus and a Suining cohort of 44 patients, we analyzed gene expression profiles and corresponding clinicopathological information. Immunohistochemistry was used to examine the expression level of FGF23 in four US subtypes. Survival analysis was used to assess the relationship between FGF23 expression and prognosis in US patients. Results Compared with uterine normal smooth muscle and uterine leiomyoma, FGF23 expression was significantly upregulated in US and was differentially expressed in four US subtypes. Uterine carcinosarcoma exhibited the highest expression of FGF23 among the subtypes. Survival analysis revealed no correlation between FGF23 expression and either overall survival or progression-free survival in US ( P > 0.05). Similar results were obtained from the validation cohorts. Univariate and multivariate analyses showed no significant correlation between FGF23 expression and the US prognosis. Tumor stage, CA125, and tumor recurrence were independent prognostic factors for survival of US patients. Conclusion FGF23 was highly expressed in US and was promising as a novel potential biomarker for the diagnosis and prognosis of US.https://doi.org/10.1177/15330338241245924 |
| spellingShingle | Ling Yang MS Ying Cai MS Yunjia Wang MS Yue Huang MS Chi Zhang MS Hu Ma MD, PhD Jian-Guo Zhou MD, PhD Fibroblast Growth Factor 23 is a Potential Prognostic Biomarker in Uterine Sarcoma Technology in Cancer Research & Treatment |
| title | Fibroblast Growth Factor 23 is a Potential Prognostic Biomarker in Uterine Sarcoma |
| title_full | Fibroblast Growth Factor 23 is a Potential Prognostic Biomarker in Uterine Sarcoma |
| title_fullStr | Fibroblast Growth Factor 23 is a Potential Prognostic Biomarker in Uterine Sarcoma |
| title_full_unstemmed | Fibroblast Growth Factor 23 is a Potential Prognostic Biomarker in Uterine Sarcoma |
| title_short | Fibroblast Growth Factor 23 is a Potential Prognostic Biomarker in Uterine Sarcoma |
| title_sort | fibroblast growth factor 23 is a potential prognostic biomarker in uterine sarcoma |
| url | https://doi.org/10.1177/15330338241245924 |
| work_keys_str_mv | AT lingyangms fibroblastgrowthfactor23isapotentialprognosticbiomarkerinuterinesarcoma AT yingcaims fibroblastgrowthfactor23isapotentialprognosticbiomarkerinuterinesarcoma AT yunjiawangms fibroblastgrowthfactor23isapotentialprognosticbiomarkerinuterinesarcoma AT yuehuangms fibroblastgrowthfactor23isapotentialprognosticbiomarkerinuterinesarcoma AT chizhangms fibroblastgrowthfactor23isapotentialprognosticbiomarkerinuterinesarcoma AT humamdphd fibroblastgrowthfactor23isapotentialprognosticbiomarkerinuterinesarcoma AT jianguozhoumdphd fibroblastgrowthfactor23isapotentialprognosticbiomarkerinuterinesarcoma |